Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer · 2026
Read Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease by Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13339365.txt.
Description
Abigail K. Mayo and colleagues simulate liver injury from obeticholic acid in fatty liver disease in a 2026 computer study. The bile acid drug won approval for a bile duct disease in 2016 but raised liver safety flags in fatty liver trials. Virtual patients replaced human dosing for the test.
Body-based models predicted drug exposure in blood, liver, and gut for healthy and fatty liver groups. Exposure was lifted two, five, and tenfold in virtual fatty liver runs as described. A toxicology model added bile transport blocking and mitochondrion harm. Predicted enzyme rises and injury plots gauge safe dose limits without exposing patients.
Catalog record
| CREATOR | Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36634 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |